How will the divestiture proceeds be allocated?

Of the approximately $980 million in proceeds, roughly $600 million will be used to repay debt and advance the company's target of net leverage below 2.0x by September 30, 2027. An additional $250 million has been authorized for the share repurchase program.

What execution methods are available under this program?

The company may execute repurchases through open-market purchases under Rule 10b-18, accelerated share repurchase (ASR) agreements, or other methods as determined by management. Actual execution will be subject to market conditions and other relevant considerations.

When is this repurchase program expected to begin?

The filing does not specify a start date for repurchases. The European divestiture transaction is expected to close in the first half of calendar 2027, subject to regulatory approvals and employee consultation requirements. Actual repurchase timing will depend on transaction completion and market conditions.

Is there a time limit on completing the $250 million repurchase?

The filing does not disclose an expiration date or specific time frame for completing the $250 million repurchase authorization. Board authorizations typically remain in effect until fully utilized, expired, or formally terminated by the board.

How does this buyback compare to James Hardie's historical capital returns?

This filing does not reference prior repurchase programs or historical buyback activity, so no direct comparison is available from the text. The $250 million authorization is presented as a one-time deployment of divestiture proceeds as part of the company's strategic portfolio realignment.

JHIUF 8-K Filed 2026-08-20 New authorization

James Hardie authorizes $250M share repurchase program

Board approves buyback alongside €840M European divestiture proceeds deployment plan

Authorization$250M

MechanismOpen-market purchases, Acceler

What the filing says

James Hardie Industries plc announced on August 20, 2026, that its Board of Directors has authorized a new $250 million share repurchase program. The authorization comes as part of the company's strategic response to proceeds from the sale of its European Fermacell business to Holcim for €840 million (approximately $980 million USD).

The company intends to deploy transaction proceeds to accelerate deleveraging and return capital to shareholders. Approximately $600 million is designated for debt repayment to advance toward the company's target of net leverage below 2.0x by September 30, 2027. Repurchases under the new program may be effected through open-market purchases, accelerated share repurchases, or other methods as determined by the company, subject to market conditions and other relevant considerations.

The European divestiture transaction is expected to close in the first half of calendar 2027, subject to customary closing conditions including regulatory approvals and required employee consultation processes.

In addition, James Hardie's Board of Directors has authorized a new $250 million share repurchase program. Repurchases may be effected through open-market purchases, accelerated share repurchases or other methods as determined by the Company, subject to market conditions and other relevant considerations. — James Hardie Industries plc 8-K filing · View on SEC EDGAR →

What this means

The $250 million authorization represents a capital return mechanism tied to proceeds from James Hardie's strategic European divestiture. Rather than a standalone buyback announcement, this authorization is part of a broader capital allocation strategy where approximately $600 million of the €840 million sale proceeds ($980 million USD) will be applied to debt reduction, and $250 million is dedicated to share repurchases. The timing of actual repurchases will depend on transaction close (expected H1 2027) and market conditions. This buyback represents a measured use of divestiture proceeds consistent with the company's stated priorities of deleveraging and shareholder returns.

Frequently asked questions

What triggered the $250 million share repurchase authorization?: James Hardie announced the authorization in connection with its strategic sale of European operations, including the Fermacell business, to Holcim for €840 million (approximately $980 million USD). The company is deploying proceeds from this divestiture to both accelerate debt reduction and return capital to shareholders through this buyback program.
How will the divestiture proceeds be allocated?: Of the approximately $980 million in proceeds, roughly $600 million will be used to repay debt and advance the company's target of net leverage below 2.0x by September 30, 2027. An additional $250 million has been authorized for the share repurchase program.
What execution methods are available under this program?: The company may execute repurchases through open-market purchases under Rule 10b-18, accelerated share repurchase (ASR) agreements, or other methods as determined by management. Actual execution will be subject to market conditions and other relevant considerations.
When is this repurchase program expected to begin?: The filing does not specify a start date for repurchases. The European divestiture transaction is expected to close in the first half of calendar 2027, subject to regulatory approvals and employee consultation requirements. Actual repurchase timing will depend on transaction completion and market conditions.
Is there a time limit on completing the $250 million repurchase?: The filing does not disclose an expiration date or specific time frame for completing the $250 million repurchase authorization. Board authorizations typically remain in effect until fully utilized, expired, or formally terminated by the board.
How does this buyback compare to James Hardie's historical capital returns?: This filing does not reference prior repurchase programs or historical buyback activity, so no direct comparison is available from the text. The $250 million authorization is presented as a one-time deployment of divestiture proceeds as part of the company's strategic portfolio realignment.

authorization divestiture-related capital-return asr-eligible rule-10b-18 industrial-sector

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.